The FDA issued a safety communication that warns about possible Guillain-Barré syndrome (GBS) with respiratory syncytial virus (RSV) vaccines manufactured by Pfizer (Abrysvo) and GSK (Arexvy).

Sales of GSK's respiratory syncytial virus (RSV) vaccine Arexvy slumped 72% in the third quarter of this year, as narrower recommendations on its use in the US started to have an effect.

Although it lowered its outlook for vaccines, including Arexvy, this was more than offset by new revenue contribution from oncology drug Blenrep and various late-stage pipeline assets. Although ...

The Therapeutic Goods Administration (TGA) has approved AREXVY to be used as a RSV vaccine for Australians aged 60 and over.

The arrangement will run for three years in the first instance and, according to GSK, also “supports potential future co-development and commercialisation of Arexvy […] for adults 60 years and ...

GSK reported a similar state of affairs Wednesday. Sales of its RSV vaccine Arexvy declined 69% year over year due to lower demand “related to a more limited recommendation ... for individuals ...

The Business Research Company's Abrysvo Or Arexvy Global market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to 2034 ...